Zanidatamab binds HER2 (ECD2/ECD4) on target cells and engages immune effectors via its Fc to induce ADCC and ADCP, and can activate complement (CDC), leading to lysis and phagocytosis of HER2+ cells; signaling blockade/internalization contribute but cytotoxicity is via Fc-mediated effector functions.